Tenaya Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Tenaya Therapeutics, Inc. (TNYA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Tenaya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.70M, a 53.22% decline year-over-year.
- Tenaya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.20M, a 41.14% decline year-over-year.
- Tenaya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.93M, a 24.90% decline year-over-year.
- Tenaya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.64M, a 21.15% decline year-over-year.
- Tenaya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $13.05M, a 20.94% decline from fiscal 2024.
- Tenaya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $16.50M, a 7.79% increase from fiscal 2023.
- Tenaya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $15.31M, a 33.50% increase from fiscal 2022.
- Tenaya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $11.47M, a 288.71% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.70M 10-Q · filed 2026-08-05 | $3.90M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $2.20M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $13.05M 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $2.93M 10-Q · filed 2025-11-10 | $6.57M derived: sum of 2 quarters · filed 2026-08-05 | $10.30M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $3.64M 10-Q · filed 2026-08-05 | $7.37M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $3.73M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $16.50M 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $3.91M 10-Q · filed 2025-11-10 | $8.52M derived: sum of 2 quarters · filed 2025-11-10 | $12.74M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $4.61M 10-Q · filed 2025-11-10 | $8.84M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $4.22M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $15.31M 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $4.01M 10-Q · filed 2024-11-06 | $7.85M derived: sum of 2 quarters · filed 2024-11-06 | $11.36M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $3.83M 10-Q · filed 2024-11-06 | $7.34M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $3.51M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $11.47M 10-K · filed 2024-03-18 | |||
| 2022-09-30 | $3.17M 10-Q · filed 2023-11-08 | $6.19M derived: sum of 2 quarters · filed 2023-11-08 | $8.28M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $3.01M 10-Q · filed 2023-11-08 | $5.11M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $2.09M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $2.95M 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $968.00K 10-Q · filed 2022-11-10 | $1.47M derived: sum of 2 quarters · filed 2022-11-10 | $1.90M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $502.00K 10-Q · filed 2022-11-10 | $934.00K derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $432.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $741.00K 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $198.00K 10-Q · filed 2021-11-10 | $383.00K derived: sum of 2 quarters · filed 2021-11-10 | $537.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $185.00K 10-Q · filed 2021-11-10 | $339.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $154.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |